IP Library Granted Patent US 10,098,943
Granted Patent B2
US 10,098,943 · App. 14/850,399 · Granted Oct 16, 2018

Flavivirus virus like particle

Inventors: Wataru Akahata (Kensington, MD); Ryuji Ueno (Easton, MD)
Assignee: VLP Therapeutics, LLC
A61K39/12C07K14/005C12N7/00A61K2039/5258A61K2039/53A61K2039/575C12N2770/24023C12N2770/24123C12N2770/24134Y02A50/386Y02A50/388Y02A50/39Y02A50/394Y02A50/396
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,943
App. No.
14/850,399
Granted
Oct 16, 2018
Kind
B2
Abstract

Provided is a virus like particle comprising one or more flavivirus structural proteins, and a composition or vaccine comprising thereof, its use in the prevention or treatment of flavivirus infection. The flavivirus structural protein contains at least one amino acid alteration in the envelope region. Examples of flavivirus contains dengue virus.

Claims (16)

1. A virus like particle comprising a flavivirus envelope protein, wherein said envelope protein comprises an amino acid substitution at position 108 of SEQ ID NO: 20, or at a position determined as corresponding to position 108 of SEQ ID NO: 20 by alignment.

2. The virus like particle according to claim 1 , wherein the flavivirus is West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, or Japanese encephalitis virus.

3. The virus like particle according to claim 2 , wherein said flavivirus is dengue virus.

4. The virus like particle according to claim 1 , wherein said virus like particle is produced from a dengue virus structural protein comprising prM and envelope regions.

5. The virus like particle according to claim 4 , wherein said structural protein comprises the amino acid sequence of residues 16-676 of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 8, 10, 14 and 16.

6. The virus like particle according to claim 4 , wherein said structural protein is a protein consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 8, 10, 14 and 16.

7. A composition comprising the virus like particle according to claim 1 and a pharmaceutically acceptable carrier.

8. The composition according to claim 7 for treating or preventing a disease or condition caused by flavivirus infection.

9. A method of producing a virus like particle, comprising culturing a cell which is transfected with a polynucleotide encoding the envelope protein contained in the virus like particle according to claim 1 ; and recovering the virus like particle from the cell culture.

10. A method of producing an antibody, comprising contacting the virus like particle according to claim 1 to a mammal.

11. The virus like particle according to claim 1 , wherein said virus like particle further comprises a prM protein.

12. The virus like particle according to claim 1 , wherein said envelope protein further comprises an amino acid substitution at position 203 of SEQ ID NO: 20, or at a position determined as corresponding to position 203 of SEQ ID NO: 20 by alignment.

13. The virus like particle according to claim 1 , wherein said envelope protein further comprises an amino acid substitution at position 246 of SEQ ID NO: 20, or at a position determined as corresponding to position 246 of SEQ ID NO: 20 by alignment.

14. The virus like particle according to claim 1 , wherein the substitution at position 108, or at the position corresponding to position 108, is the substitution of phenylalanine with alanine.

15. The virus like particle according to claim 12 , wherein the substitution at position 203, or at the position corresponding to position 203, is the substitution of lysine with asparagine.

16. The virus like particle according to claim 13 , wherein the substitution at position 246, or at the position corresponding to position 246, is the substitution of lysine with methionine.

Assignments (2)
CHANGE OF NAME Recorded May 26, 2021
From: VLP THERAPEUTICS, LLC
To: VLP THERAPEUTICS, INC.
Reel/Frame 056394/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2015
From: AKAHATA, WATARU; UENO, RYUJI
To: VLP THERAPEUTICS, LLC
Reel/Frame 036968/0915 →
Continuity (2)
Provisional Application 62048897 · Sep 11, 2014
Related Publication 20160074501A1 · Mar 17, 2016
Cited By (2)
US 12,227,770 US 12,280,102